TRANSPLANTATION AND ADOPTIVE CELLULAR THERAPY OF CANCER - THE ROLE OF T-CELL GROWTH-FACTORS

被引:3
|
作者
LOTZE, MT
机构
[1] Department of Surgery, University of Pittsburgh Medical Center, the Pittsburgh Cancer Institute, Pittsburgh
关键词
IMMUNOTHERAPY; LYMPHOKINE-ACTIVATED KILLER CELLS; TUMOR INFILTRATING LYMPHOCYTES; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-7; INTERLEUKIN-10; INTERLEUKIN-12; ADOPTIVE TRANSFER;
D O I
10.1177/096368979300200106
中图分类号
Q813 [细胞工程];
学科分类号
摘要
The ability to transfer cultured lymphocytes required the availability and the understanding of the use of the T-cell growth factors IL-2, IL-4, IL-7, and IL-12. Application of these cytokines in vitro and in vivo has allowed the modern development of adoptive transfer of tumor reactive lymphocytes to the modern immunotherapy of patients with cancer. In a randomized prospective study of IL-2 administration compared with IL-2 and lymphokine-activated killer (LAK) cells, no increase in response rate was observed. In a total of 90 patients randomized to receive LAK and IL-2 and 91 patients randomized to receive IL-2 alone, there were a total of 24 responses in patients receiving cells and IL-2 and 16 responses in those receiving IL-2 alone (no significant difference). There was some suggestion that complete responses were observed more often in melanoma patients treated with LAK and IL-2. The most interesting aspect of this study is the prolonged duration of responses, lasting for many months or years. Unfortunately, given the large numbers of variables that were examined, it became very difficult to demonstrate a clear-cut association between clinical outcome (response) and any variable that was routinely measured. Significant antitumor responses have been observed greater than expected with IL-2 alone, with the administration of tumor-infiltrating lymphocytes to patients with melanoma. We currently use hollow fiber devices (Cellco, Germantown, MD) to expand cells up through the many doublings required to generate approximately 1-2 x 10(11) cells over a period of 6 wk in culture. In a recent review of the results in patients with melanoma treated on such regimens in combination with high-dose IL-2, an approximately 20-50% response rate has been observed. The factors associated with response are still unclear. Although we initially felt that it was associated with specific lysis, subsequent studies from our group suggest that the relevant factor is specific cytokine (INF-gamma, GM-CSF, TNF) production upon tumor stimulation. Additional studies will need to be done to clarify these issues.
引用
收藏
页码:33 / 47
页数:15
相关论文
共 50 条
  • [1] NEW T-CELL GROWTH-FACTORS IN THE TREATMENT OF CANCER
    LOTZE, MT
    RUBIN, JT
    STORKUS, WJ
    HURD, S
    NASTALA, CL
    EDINGTON, HE
    MCKINNEY, TG
    PIPPIN, B
    NISHIHARA, K
    TAHARA, H
    ELDER, E
    WHITESIDE, T
    ZIMMERMAN, R
    LOUIE, A
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 59 - 59
  • [2] T-CELL GROWTH-FACTORS AND THE TREATMENT OF PATIENTS WITH CANCER
    LOTZE, MT
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1992, 62 (01): : S47 - S54
  • [3] Adoptive T-cell therapy of cancer
    Erbayraktar, Z.
    JOURNAL OF BUON, 2009, 14 : S193 - S201
  • [4] Adoptive T-cell therapy of cancer
    Yee, Cassian
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2006, 20 (03) : 711 - 733
  • [5] Adoptive T-Cell Therapy for Cancer
    Yang, James C.
    Rosenberg, Steven A.
    TUMOR IMMUNOLOGY, 2016, 130 : 279 - 294
  • [6] The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation
    Sellar, Rob S.
    Peggs, Karl S.
    CYTOTHERAPY, 2012, 14 (04) : 391 - 400
  • [7] HELPER T-CELL GROWTH REQUIREMENTS - ROLE OF GROWTH-FACTORS AND SPECIFIC CLONAL RECOGNITION
    BANDEIRA, A
    POBOR, G
    PETTERSSON, S
    COUTINHO, A
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1982, 16 (05) : 444 - 444
  • [8] Adoptive T-cell therapy
    Lokhorst, HM
    Liebowitz, D
    SEMINARS IN HEMATOLOGY, 1999, 36 (01) : 26 - 29
  • [9] Exploiting cytokines in adoptive T-cell therapy of cancer
    Petrozziello, Elisabetta
    Sturmheit, Tabea
    Mondino, Anna
    IMMUNOTHERAPY, 2015, 7 (05) : 573 - 584
  • [10] A universal killer T-cell for adoptive cell therapy of cancer
    Dillard, Pierre
    Mensali, Nadia
    Myklebust, June Helen
    Hebeisen, Mickael
    Skorstad, Gjertrud
    Myrhe, Marit Renee
    Fane, Anne
    Gaudernack, Gustav
    Kvalheim, Gunnar
    Inderberg, Else Marit
    Walchli, Sebastien
    CANCER RESEARCH, 2018, 78 (13)